Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 205.74M P/E - EPS this Y 72.40% Ern Qtrly Grth -
Income -276.13M Forward P/E -1.10 EPS next Y 36.10% 50D Avg Chg 12.00%
Sales 8.57M PEG - EPS past 5Y - 200D Avg Chg -35.00%
Dividend N/A Price/Book 3.12 EPS next 5Y - 52W High Chg -65.00%
Recommedations 2.70 Quick Ratio 0.61 Shares Outstanding 119.36M 52W Low Chg 45.00%
Insider Own 2.77% ROA -62.11% Shares Float 90.82M Beta 0.72
Inst Own 60.38% ROE -2,014.86% Shares Shorted/Prior 11.45M/11.03M Price 2.10
Gross Margin - Profit Margin - Avg. Volume 1,890,551 Target Price 4.20
Oper. Margin -1,922.44% Earnings Date May 6 Volume 1,101,844 Change -2.33%
About Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Atara Biotherapeutics, Inc. News
04/05/24 Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
03/28/24 Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates
03/28/24 Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
02/29/24 Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy
02/28/24 Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference
02/14/24 Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis
02/03/24 After losing 76% in the past year, Atara Biotherapeutics, Inc. (NASDAQ:ATRA) institutional owners must be relieved by the recent gain
01/31/24 Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-celยฎ Data in The Lancet Oncology
01/11/24 Seth Klarman's Exit from Atara Biotherapeutics Inc
01/11/24 Seth Klarman's Firm Exits Atara Biotherapeutics Inc Holding
01/08/24 Atara Biotherapeutics Announces $15 Million Registered Direct Offering
01/08/24 Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conference
01/04/24 Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
12/20/23 Atara Biotherapeutics Announces Closing of Expanded Global Tab-celยฎ Partnership with Pierre Fabre Laboratories
12/11/23 Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting
04:01 PM Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/29/23 Atara Biotherapeutics To Present Positive New Tab-celยฎ Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023
11/24/23 Atara Biotherapeutics (ATRA) Slumps 57% in a Month: Here's Why
11/22/23 Atara Biotherapeutics to Participate at the 6th Annual Evercore ISI HealthCONx Conference
11/22/23 Billionaire Seth Klarmanโ€™s Biotech Stock Picks
ATRA Chatroom

User Image shoagh12 Posted - 5 hours ago

$ATRA 1$ End of the week

User Image Pegy Posted - 5 hours ago

$ATRA so what is going on here? Are we going to get some traction?

User Image shoagh12 Posted - 6 hours ago

$ATRA

User Image takingstock73 Posted - 10 hours ago

$ATRA who's got the next catalyst date for this sleeper?

User Image Gunnar1 Posted - 04/30/24

$SPRB At current level SPRB is like $ATRA in the high 0.4's or $ACRS in the 0.8's (both after their gap downs last year). Just my opinion.

User Image stockrockinbeats Posted - 04/29/24

$ATRA

User Image Pegy Posted - 04/28/24

$ATRA

User Image Pegy Posted - 04/26/24

$ATRA again

User Image Pegy Posted - 04/24/24

$ATRA I really feel lonely here where is everybody?๐Ÿš€๐Ÿš€๐Ÿ’ฐ

User Image Pegy Posted - 04/23/24

$ATRA what is going on? On this board. Where is everybody. We are ready to take off and no-one cares? ๐Ÿš€๐Ÿš€๐Ÿš€๐Ÿš€๐Ÿ’ช

User Image Stmkr Posted - 04/21/24

$ATRA $CABA $KYTX Beyond ATRA are there others developing an allogeneic (vs autologous) CAR-T for autoimmune indications? To my understanding both CABA's and KYTX's clinical stage assets are autologous. KYTX has an allogeneic CAR-T asset but still in the preclinical stage.

User Image takingstock73 Posted - 04/19/24

$ATRA been pretty quiet here

User Image shoagh12 Posted - 04/19/24

$ATRA 1$ soon

User Image Crivit Posted - 04/17/24

$ATRA The last trading days showed strange trading behavior!

User Image takingstock73 Posted - 04/17/24

$ATRA anyone have a read on the next catalyst for this sleeping giant?

User Image Zweiaugen Posted - 04/16/24

$ATRA

User Image Zweiaugen Posted - 04/16/24

$ATRA Today 0.85 USD

User Image Zweiaugen Posted - 04/16/24

$ATRA Atara will fly soon

User Image Glenmorangie18yr Posted - 04/14/24

$ATRA In an ocean of red where Bios are getting decimated this is holding up like a champ ๐Ÿ‘๐Ÿท๐Ÿฅƒ

User Image cass123 Posted - 04/12/24

$ATRA Usual beating at the last second of trading...wth

User Image shoagh12 Posted - 04/11/24

$ATRA

User Image Niceo1337 Posted - 04/11/24

$ATRA Lets go โค๏ธโ˜๐Ÿป๐Ÿ“ˆ

User Image Glenmorangie18yr Posted - 04/09/24

$ATRA It's a hard slog for this ticker. So many heavy resistance areas. It keeps forming symmetrical triangles, consolidates, break out and forms another. It's a slow move for now, BUT, it's moving in the right direction. Still waiting on full data readout as well. Hope they release it when the market is in better shape and XBI is going back up. ๐Ÿท๐Ÿฅƒ

User Image Crivit Posted - 04/09/24

$ATRA Compared to the last few days, we had a high volume after hours yesterday:

User Image cass123 Posted - 04/08/24

$ATRA Shorts always have fun with us at the end of the day. Damn

User Image shoagh12 Posted - 04/08/24

$ATRA fly tomorrow

User Image Jizzle14 Posted - 04/08/24

$ATRA I'm confident we will report better numbers than last yr Q1 ๐Ÿ˜ƒ. 1 month countdown. Over $1 by then?

User Image shoagh12 Posted - 04/08/24

$ATRA 1 $ today

User Image Stock_Titan Posted - 04/05/24

$ATRA Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://www.stocktitan.net/news/ATRA/atara-biotherapeutics-inc-reports-inducement-grant-under-nasdaq-59un23r5atf7.html

User Image shoagh12 Posted - 04/05/24

$ATRA fly to 1

Analyst Ratings
Stifel Hold Apr 1, 24
Goldman Sachs Sell Nov 10, 23
Evercore ISI Group In-Line Nov 9, 23
HC Wainwright & Co. Neutral Nov 9, 23
Mizuho Neutral Nov 9, 23
HC Wainwright & Co. Buy Sep 26, 23
Citigroup Sell Aug 21, 23
EF Hutton Buy Aug 9, 23
HC Wainwright & Co. Buy Jun 14, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Gallagher Carol Giltner Director Director Nov 13 Buy 0.27 270,000 72,900 459,418 11/15/23
HEIDEN WILLIAM K Director Director Nov 10 Buy 0.2533 100,000 25,330 209,000 11/14/23
DOBMEIER ERIC Director Director Nov 10 Buy 0.2268 446,825 101,340 563,325 11/14/23
Hyllengren Eric J SVP, CFO SVP, CFO Aug 16 Sell 1.65 8,186 13,507 217,956 08/18/23
Murugan Amar EVP, Chief Legal Off.. EVP, Chief Legal Officer Aug 16 Sell 1.65 8,672 14,309 265,391 08/18/23
Touchon Pascal President and CEO President and CEO Aug 16 Sell 1.65 30,766 50,764 675,905 08/18/23
Nguyen AnhCo EVP, Chief Sci. & Te.. EVP, Chief Sci. & Tech Officer Aug 16 Sell 1.65 15,126 24,958 285,999 08/18/23
Joshi Manher EVP, Chief Medical O.. EVP, Chief Medical Officer Aug 16 Sell 1.65 6,975 11,509 183,571 08/18/23
Henrich Jill EVP, Global Head RA.. EVP, Global Head RA & Quality Aug 16 Sell 1.65 3,346 5,521 107,691 08/18/23
Murugan Amar EVP, Chief Legal Off.. EVP, Chief Legal Officer May 16 Sell 2.04 8,389 17,114 270,945 05/18/23
Banard Charlene A. EVP, Chief Technical.. EVP, Chief Technical Officer May 16 Sell 2.037 19,040 38,784 276,010 05/18/23
Touchon Pascal President and CEO President and CEO May 16 Sell 2.037 29,766 60,633 720,962 05/18/23
Hyllengren Eric J SVP, CFO SVP, CFO May 16 Sell 2.04 7,918 16,153 226,142 05/18/23
Touchon Pascal President and CEO President and CEO Mar 02 Sell 3.627 15,679 56,868 750,728 03/06/23
Murugan Amar SVP, GC & Secretary SVP, GC & Secretary Mar 02 Sell 3.627 4,221 15,310 279,334 03/06/23
Koppikar Utpal Chief Financial Offi.. Chief Financial Officer Mar 02 Sell 3.627 6,871 24,921 181,978 03/06/23
Dupont Jakob EVP, Head of R&D EVP, Head of R&D Mar 02 Sell 3.627 5,074 18,403 290,794 03/06/23
Koppikar Utpal Chief Financial Offi.. Chief Financial Officer Feb 07 Sell 5.46 2,485 13,568 188,849 02/09/23
Dupont Jakob EVP, Head of R&D EVP, Head of R&D Nov 16 Sell 4.49 4,342 19,496 154,540 11/18/22
Touchon Pascal President and CEO President and CEO Nov 16 Sell 4.49 15,591 70,004 441,696 11/18/22
Murugan Amar SVP, GC & Secretary SVP, GC & Secretary Nov 16 Sell 4.49 3,612 16,218 127,586 11/18/22
Koppikar Utpal Chief Financial Offi.. Chief Financial Officer Nov 16 Sell 4.49 6,255 28,085 191,334 11/18/22
Touchon Pascal President and CEO President and CEO Aug 16 Sell 5.035 14,806 74,548 457,287 08/18/22
Dupont Jakob EVP, Head of R&D EVP, Head of R&D Aug 16 Sell 5.034 4,124 20,760 158,882 08/18/22
Murugan Amar SVP, GC & Secretary SVP, GC & Secretary Aug 16 Sell 5.03 3,430 17,253 131,198 08/18/22
Koppikar Utpal Chief Financial Offi.. Chief Financial Officer Aug 16 Sell 5.035 5,940 29,908 197,589 08/18/22
Touchon Pascal President and CEO President and CEO Jun 27 Sell 7.20 14,220 102,384 472,093 06/29/22
Murugan Amar SVP, GC & Secretary SVP, GC & Secretary May 17 Sell 5.32 3,223 17,146 133,735 05/19/22
Koppikar Utpal Chief Financial Offi.. Chief Financial Officer May 17 Sell 5.32 5,582 29,696 207,592 05/19/22
Dupont Jakob EVP, Head of R&D EVP, Head of R&D May 17 Sell 5.318 3,873 20,597 163,006 05/19/22
Touchon Pascal President and CEO President and CEO May 17 Sell 5.316 13,913 73,962 486,313 05/19/22
Koppikar Utpal Chief Financial Offi.. Chief Financial Officer Mar 01 Sell 9.86 3,763 37,103 213,174 03/03/22
Dupont Jakob EVP, Head of R&D EVP, Head of R&D Mar 01 Sell 9.86 2,221 21,899 166,879 03/03/22
Touchon Pascal President and CEO President and CEO Mar 01 Sell 9.86 8,828 87,044 500,226 03/03/22
Murugan Amar SVP, GC & Secretary SVP, GC & Secretary Mar 01 Sell 9.86 2,577 25,409 136,958 03/03/22
Dupont Jakob EVP, Head of R&D EVP, Head of R&D Feb 10 Option 9.58 5,000 47,900 95,594 02/14/22
Dupont Jakob EVP, Head of R&D EVP, Head of R&D Feb 10 Sell 16 5,000 80,000 90,594 02/14/22
Newell Joe Chief Operations Off.. Chief Operations Officer Dec 18 Option 12.15 3,500 42,525 120,055 12/18/20
Newell Joe Chief Operations Off.. Chief Operations Officer Dec 18 Sell 23.11 7,000 161,770 113,055 12/18/20